N-Cyclopropyltryptamine (NcPT) is a monoamine oxidase inhibitor (MAOI) of the tryptamine family related to N-methyltryptamine (NMT). "Another provocative mono-alkyl analogue of DMT is N-cyclopropyltryptamine, made from indole-3-oxalylchloride and benzyl cyclopropylamine with eventual hydrogenolysis of the benzyl group; mp 180–182. This compound, as with the 5-methoxy (5-MeO-NCPT) and the 7-methoxy (7-MeO-NCPT) counterparts, is a potent monoamine-oxidase inhibitor, and it has also been reported to have hypoglycemic activity."
It is a potent MAOI, with greater activity than pargyline (56–67% inhibition at 100nM versus 41% inhibition at 100nM, respectively). The drug markedly potentiates the behavioral effects of 5-hydroxytryptophan (5-HTP) in rodents. In addition, it produces tremors, hypolocomotion, motor incoordination, and vasodilation in rodents. NcPT has also been reported to have antihyperglycemic activity. The drug has not been assessed in terms of psychedelic-related behavioral effects.
The chemical synthesis of NcPT has been described. Some notable derivatives of NcPT include 5-MeO-NcPT, 7-MeO-NcPT, 5,6-DiMeO-NcPT, and 6,7-DiMeO-NcPT, which showed MAOI activity similarly to NcPT. Some other derivatives include the psychedelic designer drugs N-methyl-N-cyclopropyltryptamine (McPT), 4-HO-McPT, and 4-AcO-McPT.
NcPT was first described in the scientific literature by 1975.
See also Substituted tryptamine
References
External links NcPT - Isomer Design